Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Status:
Completed
Trial end date:
2016-06-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of a moderate Cytochrome P450 (CYP) 3A
inhibitor (erythromycin) and a strong CYP3A inhibitor (voriconazole) on the steady-state
pharmacokinetics (PK [the study of the way a drug enters and leaves the blood and tissues
over time]) of repeated oral doses of ibrutinib in participants with B-cell malignancy
(cancer or other progressively enlarging and spreading tumors).